New EU Fee System To Give Pharma Firms More Predictability
Executive Summary
The publication of a draft EU Regulation governing the fees paid by the pharmaceutical industry to the European Medicines Agency is the latest step in a long process aimed at ensuring that the payment system better reflects the actual costs of the regulatory work carried out or coordinated by the EU regulator.
You may also be interested in...
EU Bodies Agree On Ways To Future-Proof EMA Funding System
EU ministers say that implementing an appropriate fee structure that is more in line with actual costs will promote innovation in the pharmaceutical sector while ensuring “fair access” to safe and effective medicines for patients.
EU Ministers Back Greater Role For Member States In Updating EMA Fees
The Council of the EU has broadly accepted the European Commission’s proposal for a new, cost-based fee and remuneration system, but has suggested giving the European Medicines Agency’s management board – and hence the member states – a bigger role in future fee changes.
EU Ministers Want More Targeted Approach To New EMA Fees
Proposals for a new cost-based fee structure at the European Medicines Agency are to be discussed by EU member state health ministers next week, with calls for more targeted fee rises for specific services on the agenda.